D-alanyl-D-alanine terminus of cell wall precursors — Drug Target

All drugs that target D-alanyl-D-alanine terminus of cell wall precursors — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

glycopeptide antibiotic

Phase 3 pipeline (4)

• Vancomycin (or equivalent) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · glycopeptide antibiotic · Infectious Diseases
  Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.
• Vancomycin capsules · Astellas Pharma Europe B.V. · glycopeptide antibiotic · Infectious Diseases
  Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.
• Vancomycin 1.1% · Kurobe LLC · glycopeptide antibiotic · Infectious Disease
  Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.
• Vancomycin oral liquid · Astellas Pharma Europe B.V. · glycopeptide antibiotic · Infectious Diseases
  Vancomycin oral liquid inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of cell wall precursors.